A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
Interventions: DRUG: Trastuzumab deruxtecan
Sponsor: AstraZeneca
Collaborators: Daiichi Sankyo Co., Ltd.